Xeris Biopharma Holdings (XERS) EPS (Basic) (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly EPS (Basic) came in at -$0.18 in Q2 2026, down 1388.38% on a YoY basis from $0.01 in Q2 2025, and down 1473.64% quarter-over-quarter from $0.01 in Q1 2026.
Powered by 
Analysis
Xeris Biopharma Holdings (XERS) EPS (Basic) (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has reported EPS (Basic) for 7 consecutive years, with -$0.18 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) fell 1388.38% year-over-year to -$0.18; the trailing twelve-month figure through Jun 2026 stood at -$0.1 (up 50.51% YoY), and the FY2025 full-year result was $0.0, up 100.92% from the prior year.
- EPS (Basic) eased to -$0.18 in Q2 2026 per XERS's latest filing, from $0.01 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.07 in Q4 2025 and bottomed at -$0.25 in Q1 2022.
- Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of -$0.1 in 2023.
- The sharpest annual moves came in 2025 and 2026: EPS (Basic) jumped 298.28% in 2025, then slumped 1388.38% in 2026.
- Over 5 years, EPS (Basic) stood at -$0.1 in 2022, then declined by 2.02% to -$0.1 in 2023, then soared by 64.18% to -$0.03 in 2024, then surged by 298.28% to $0.07 in 2025, then plunged by 360.53% to -$0.18 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.18, $0.01, and $0.07 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 2.30 |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 2.04 |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | -0.54 |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 1.68 |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -0.04 |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | 0.33 |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | -3.06 |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 2.92 |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 7.82 |
| 10 | Xeris Biopharma Holdings | 1.38 Bn | 1.26 Bn | 79.59 Mn | -0.18 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.18 |
| Mar 31, 2026 | 0.01 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | -0.01 |
| Mar 31, 2025 | -0.06 |
| Dec 31, 2024 | -0.03 |
| Sep 30, 2024 | -0.11 |
| Jun 30, 2024 | -0.10 |
| Mar 31, 2024 | -0.14 |
| Dec 31, 2023 | -0.10 |
| Sep 30, 2023 | -0.09 |
| Jun 30, 2023 | -0.14 |
| Mar 31, 2023 | -0.12 |
| Dec 31, 2022 | -0.10 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.19 |
| Mar 31, 2022 | -0.25 |
| Dec 31, 2021 | -0.64 |
| Sep 30, 2021 | -0.39 |